QIAstat-Dx Meningitis/Encephalitis Panel cleared in the U.S. for use in clinical settings to help diagnose central nervous system infections // Fourth ...
Novo Nordisk presented an exploratory post hoc analysis from the SELECT phase 3 cardiovascular outcomes trial that showed semaglutide 2.4 mg significantly ...
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24%compared to the third quarter of 2023 Placed seven Growth Direct&...
November is Lung Cancer Awareness Month, and the American Lung Association (Lung Association) is kicking it off by offering free lung cancer screenings to&...
Bayer has launched a first-of-its-kind in the healthcare industry, polyethylene terephthalate (PET) blister packaging on its renowned brand, Aleve. Reali...
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, announced financial r...
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates announced a significant expansion in their quality control (QC) test...
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...
JBI-802 is a first-in-class, orally administered, inhibitor of CoREST complex JBI-778 is a potential best-in-class, orally ad...
Net sales of $1.71 billion, decrease of 0.3%; organic decline of 0.7% Net income of $57.8 million; Adjusted EBITDA of $302.5 milli...
Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing...
Bora Pharmaceuticals Co., Ltd. ("Bora" or "the Company", TWSE: 6472), announced that its Board of Directors has approved the acquisition of US-based ...
AbbVie (NYSE: ABBV) and Gedeon Richter Plc. ('Richter') announced a new discovery, co-development and license agreement to advance novel targets for ...
Positive data from the phase 3 LIBERTY-CUPID Study C evaluating the investigational use of Dupixent (dupilumab) in biologic-naive patients with uncontrolle...
© 2025 Biopharma Boardroom. All Rights Reserved.
